Colloid solutions for fluid resuscitation in patients with sepsis: systematic review of randomized controlled trials.
BACKGROUND
Colloids are widely used for fluid resuscitation in patients with sepsis. But the optimal type of fluid remains unclear.


OBJECTIVE
Our aim was to assess the effects on mortality and safety of different colloid solutions in patients with sepsis requiring volume replacement by examining direct comparisons of colloid solutions.


METHODS
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, China Biological Medicine Database, VIP Chinese Journals Database, and CNKI China National Knowledge Infrastructure Whole Article Database. Randomized clinical trials comparing different colloids in septic patients needing fluid resuscitation were selected.


RESULTS
Seventeen randomized clinical trials with a total 1281 participants met the inclusion criteria. Mortality was obtained in all trials. For intervention of albumin vs. hydroxyethyl starch solution (HES), the relative risk (RR) of death was 0.98 (95% confidence interval [CI] 0.74-1.30). For intervention of albumin vs. gelatin, the RR of death was 2.4 (95% CI 0.31-18.35). For intervention of gelatin vs. HES, the RR of death was 1.02 (95% CI 0.79-1.32). For the intervention of HES vs. dextran, the RR of death was 1.38 (95% CI 0.28-6.78). For the intervention of gelatin vs. dextran, RR of death was not estimable. For albumin vs. dextran, no trial was included. Four trials of intervention of albumin vs. HES recorded the change of severity score.


CONCLUSIONS
There is no evidence that one colloid solution is more effective and safer than another for fluid resuscitation in sepsis. The severity score is improved in HES, but the confidence intervals are wide.
Department of Pediatrics, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China.
Jing-Zi
JZ
Zhong
Dan
D
Wei
Hong-Fei
HF
Pan
Yu-Jun
YJ
Chen
Xiu-An
XA
Liang
Zhi-Yong
ZY
Yang
Hua-Bo
HB
Tang
D000418:Albumins / Q000627:therapeutic use; D003102:Colloids / Q000009:adverse effects / Q000627:therapeutic use*; D003911:Dextrans / Q000627:therapeutic use; D005440:Fluid Therapy; D005780:Gelatin / Q000627:therapeutic use; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018805:Sepsis / Q000401:mortality / Q000628:therapy*
D000418:Albumins; D003102:Colloids; D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D005780:Gelatin
colloids; fluid resuscitation; sepsis; systemic review